ArticleFrontiers in immunology2024
The type 1 diabetes susceptibility locus
Jérémy C Santamaria, Sylvia Vuillier, Ariel O Galindo-Albarrán, Sarah Castan, Claire Detraves, Olivier P Joffre, Paola Romagnoli, Joost P M van Meerwijk
Open access · goldAbstract read
In one paragraphArticle in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 1 institution in 1 country.
Jérémy C Santamaria *Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Sylvia Vuillier *Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Ariel O Galindo-AlbarránToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Sarah CastanToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Claire DetravesToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Olivier P JoffreToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Paola RomagnoliToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Joost P M van MeerwijkToulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut National de la santé et de la recherche médicale (Inserm) UMR1291 - Centre national de la recherche scientifique (CNRS) UMR5051 - University Toulouse III, Toulouse, France.
Centre National de la Recherche Scientifique · FR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Regulatory T lymphocytes expressing the transcription factor Foxp3 (Tregs) play an important role in the prevention of autoimmune diseases and other immunopathologies. Aberrations in Treg-mediated immunosuppression are therefore thought to be involved in the development of autoimmune pathologies, but few have been documented. Recent reports indicated a central role for Tregs developing during the neonatal period in the prevention of autoimmune pathology. We therefore investigated the development of Tregs in neonatal NOD mice, an important animal model for autoimmune type 1 diabetes. Surprisingly, we found that, as compared with seven other commonly studied inbred mouse strains, in neonatal NOD mice, exceptionally large proportions of developing Tregs express high levels of GITR and PD-1. The latter phenotype was previously associated with high Treg autoreactivity in C57BL/6 mice, which we here confirm for NOD animals. The proportions of newly developing GITR
Indexed as
Diabetes Mellitus, Type 1AnimalsMiceMice, Inbred C57BLMice, Inbred NODProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryTranscription FactorsProgrammed Cell Death 1 ReceptorTranscription FactorsIdd5immune toleranceregulatory T cellsthymustype 1 diabetes
Identifiers
PMID38404576
PMCPMC10884962
OpenAlexW4391680637
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390